HBV Epitope Binding Molecule for Escape Mutant Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B, including nucleoside analogues and hepatitis B immune globulin, face challenges such as drug resistance, high production costs, and limited efficacy, particularly in preventing vertical transmission and re-infection in liver transplant patients, while conventional vaccines struggle with recognizing escape mutants.
Innovation Solution
Development of an epitope on the hepatitis B virus surface antigen (HBsAg) including amino acids at positions 110, 118, 120, and/or 147, and a corresponding HBV-neutralizing binding molecule that maintains a three-dimensional structure, enabling effective binding and neutralization of HBV, including resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines targeting the α-determinant (amino acids 124-147) are used, then immunity against HBV is provided, but escape mutants can develop that recognize and evade these antibodies
Solution Approach 1:
The patent applies local quality by shifting the antibody binding target from the conventional α-determinant region (amino acids 124-147) to a new epitope region (amino acids 110-120 and 147). This localized change in binding specificity allows the antibody to recognize a different structural region that is less prone to mutation, thereby maintaining reliable immunity while avoiding escape mutant evasion.
Solution Approach 2:
The patent segments the HBsAg protein into distinct epitope regions, specifically identifying amino acids 110-120 and 147 as critical binding sites. By focusing on this segmented region rather than the entire α-determinant, the invention creates antibodies with specialized recognition capabilities that are less susceptible to mutant escape.
2Reliability
If hepatitis B immune globulin (HBIg) is used to prevent vertical transmission and re-infection, then protection is provided, but material plasma is difficult to obtain requiring excessive importation costs and time-consuming virus removal processes
Solution Approach 1:
The patent creates a synthetic copy of the protective antibody function by engineering recombinant antibodies that replicate the neutralizing activity of HBIg. Instead of relying on plasma-derived HBIg, the invention produces identical or equivalent protective antibodies through recombinant DNA technology in cell cultures, eliminating the need for plasma importation and extensive virus removal processes while maintaining protection against vertical transmission.
Solution Approach 2:
The patent replaces the mechanical/plasma-based HBIg production system with a biological/recombinant system. By using recombinant DNA technology to express antibody genes in host cells, the invention substitutes the complex plasma purification and virus inactivation process with a more efficient and scalable biotechnological production method.
3Reliability
If nucleoside analogues are used for long-term treatment, then viral DNA replication is suppressed, but drug resistance develops deteriorating drug efficacy
Solution Approach 1:
The patent inverts the conventional treatment approach by switching from suppressing viral replication (nucleoside analogues) to directly neutralizing the virus through antibody binding. Instead of inhibiting the viral reverse transcriptase enzyme, the invention uses antibodies that bind to HBsAg epitopes, blocking viral assembly and release, thereby suppressing replication through a different mechanism that does not select for the same resistance mutations.
Solution Approach 2:
The patent introduces an intermediary substance (recombinant antibody) that mediates the neutralization of HBV. This antibody acts as a bridge between the host immune system and the virus, providing sustained protection without the direct selective pressure that leads to nucleoside analogue resistance. The antibody-virus complex formed through this intermediary mechanism prevents viral replication without inducing resistance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The epitope and binding molecule provide a novel approach for preventing and treating hepatitis B by effectively neutralizing HBV across various genotypes and resistant strains, reducing the risk of escape mutants and improving treatment efficacy.
Implementation Method 1
a hepatitis B virus-neutralizing binding molecule specifically binding thereto
Data Source
AI summary
The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.